These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30298710)

  • 41. Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6.
    Mehta V; Rycyna K; Baesens BM; Barkan GA; Paner GP; Flanigan RC; Wojcik EM; Venkataraman G
    Int J Clin Exp Pathol; 2012; 5(6):496-502. PubMed ID: 22949931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
    Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
    Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of Prostate Specific Antigen Level on Oncological Outcomes after Open Radical Prostatectomy.
    Sungur M; Caliskan S
    J Coll Physicians Surg Pak; 2019 Apr; 29(4):361-364. PubMed ID: 30925962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.
    Lucarelli G; Fanelli M; Larocca AM; Germinario CA; Rutigliano M; Vavallo A; Selvaggi FP; Bettocchi C; Battaglia M; Ditonno P
    Prostate; 2012 Nov; 72(15):1611-21. PubMed ID: 22430630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).
    Chung JH; Yu J; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
    J Korean Med Sci; 2020 Oct; 35(41):e342. PubMed ID: 33107227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Risk factors of ISUP Modified Gleason score upgrading after radical prostatectomy].
    Li XD; Qu GY; Xu N; Xue XY; Wei Y; Zheng QS; Li JF; Cai H; Lin YZ
    Zhonghua Nan Ke Xue; 2016 May; 22(5):415-9. PubMed ID: 27416665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
    Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
    Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Body Mass Index and prostatic-specific antigen are predictors of prostate cancer metastases in patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection.
    Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Cacciamani GE; Brunelli M; Siracusano S; Cerruto MA; Artibani W
    Minerva Urol Nefrol; 2019 Oct; 71(5):516-523. PubMed ID: 31241272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
    Verep S; Erdem S; Ozluk Y; Kilicaslan I; Sanli O; Ozcan F
    Prostate; 2019 Sep; 79(13):1523-1529. PubMed ID: 31269285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.
    Thomas C; Pfirrmann K; Pieles F; Bogumil A; Gillitzer R; Wiesner C; Thüroff JW; Melchior SW
    BJU Int; 2012 Jan; 109(2):214-9. PubMed ID: 21592293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer.
    Sanguedolce F; Falagario UG; Castellan P; Di Nauta M; Silecchia G; Bruno SM; Russo D; Treacy PJ; Tewari AK; Montironi R; Carrieri G; Cormio L
    Urol Oncol; 2020 Oct; 38(10):793.e19-793.e25. PubMed ID: 32220548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
    Braun AE; Chan JM; Neuhaus J; Cowan JE; Kenfield SA; Van Blarigan EL; Tenggara I; Broering JM; Simko JP; Carroll PR; Cooperberg MR
    Cancer; 2024 May; 130(10):1766-1772. PubMed ID: 38280206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.
    Dinh KT; Mahal BA; Ziehr DR; Muralidhar V; Chen YW; Viswanathan VB; Nezolosky MD; Beard CJ; Choueiri TK; Martin NE; Orio PF; Sweeney CJ; Trinh QD; Nguyen PL
    J Urol; 2015 Aug; 194(2):343-9. PubMed ID: 25681290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High risk of under-grading and -staging in prostate cancer patients eligible for active surveillance.
    Heidegger I; Skradski V; Steiner E; Klocker H; Pichler R; Pircher A; Horninger W; Bektic J
    PLoS One; 2015; 10(2):e0115537. PubMed ID: 25658878
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Impact of Visible Tumor (PI-RADS ≥ 3) on Upgrading and Adverse Pathology at Radical Prostatectomy in Low Risk Prostate Cancer Patients: A Biopsy Core Based Analysis.
    Özkan A; Köseoğlu E; Kılıç M; Baydar DE; Sağlıcan Y; Balbay MD; Canda AE; Kordan Y; Kiremit MC; Çil B; Tuğcu V; Bakır B; Esen T
    Clin Genitourin Cancer; 2022 Feb; 20(1):e61-e67. PubMed ID: 34750082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance.
    Ploussard G; de la Taille A; Terry S; Allory Y; Ouzaïd I; Vacherot F; Abbou CC; Salomon L
    Urol Oncol; 2013 Oct; 31(7):1060-6. PubMed ID: 22300755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinically predictive factors of Gleason score upgrading in patients after radical prostatectomy].
    Zuo Q; Zhang F; Huang Y; Ma LL; Lu M; Lu J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):603-606. PubMed ID: 29263497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate cancer volume at biopsy predicts clinically significant upgrading.
    Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
    J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.